Co-Marketing of Capillary Electrophoresis/Laser-Induced Fluorescence Solutions
News Aug 23, 2005
Agilent Technologies Inc. and Picometrics S.A. have announced a nonexclusive co-marketing agreement for Picometrics' Laser Induced Fluorescence (LIF) detection systems combined with Agilent's Capillary Electrophoresis (CE) system.
"Picometrics' LIF detectors will bring the benefits of fluorescence detection, such as sensitivity and selectivity, to Agilent CE users," said Tony Owen, Agilent marketing manager, Liquid Phase Analysis Products.
He adds, "This agreement will improve integration of these highly complementary technologies to provide solutions for the pharmaceutical as well as environmental industries."
Further he said, "The collaboration will address the increasing need for sensitive detection of peptides, proteins and nucleic acids, and the difficulties in the analysis of carbohydrates, amino acids and catecholamines."
"This agreement brings together two leading platforms to provide the best solution in research and quality-control laboratories," said Bernard Feurer, president and CEO of Picometrics.
He adds, "Our customers will benefit from the combined expertise of Agilent and Picometrics, with the offering of a range of CE-LIF solutions to address specific applications."
This collaboration will enable the development and marketing of existing CE-LIF applications.
According to Picometrics, the ZETALIF detectors are the sensitive and modular LIF detectors available. The company offers 14 excitation laser sources for a wide range of applications and frequently upgrades the product line.
Picometrics claims that, the Agilent CE is easily coupled to the LIF detector using the external detector cassette. The LIF signal is integrated into the ChemStation process using an A/D converter.
The same LIF detector with no modification can be used as well, coupled to a wide range of LC separation systems.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.